Microbot Medical (NASDAQ:MBOT) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.99 and traded as high as $2.54. Microbot Medical shares last traded at $2.49, with a volume of 903,804 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research note on Thursday, April 10th. Wall Street Zen raised shares of Microbot Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th.

Microbot Medical Trading Up 4.0%

The business's 50-day moving average is $2.55 and its two-hundred day moving average is $2.02. The stock has a market capitalization of $94.59 million, a PE ratio of -4.00 and a beta of 1.13.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. On average, analysts predict that Microbot Medical Inc. will post -0.71 EPS for the current year.

Institutional Trading of Microbot Medical

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Microbot Medical during the 1st quarter worth $42,000. Goldman Sachs Group Inc. purchased a new position in Microbot Medical in the 1st quarter valued at about $57,000. Renaissance Technologies LLC purchased a new position in Microbot Medical in the 4th quarter valued at about $118,000. Finally, Geode Capital Management LLC boosted its position in Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after buying an additional 10,442 shares during the last quarter. 16.30% of the stock is owned by hedge funds and other institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.